Is Enhabit, Inc. (EHAB) Stock Outpacing Its Medical Peers This Year?

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Enhabit (EHAB) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.Enhabit is a member of the Medical sector. This group includes 947 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Enhabit is currently sporting a Zacks Rank of #2 (Buy).Over the past three months, the Zacks Consensus Estimate for EHAB's full-year earnings has moved 12.4% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.According to our latest data, EHAB has moved about 23.2% on a year-to-date basis. Meanwhile, stocks in the Medical group have gained about 5.8% on average. This means that Enhabit is outperforming the sector as a whole this year.One other Medical stock that has outperformed the sector so far this year is Gain Therapeutics, Inc. (GANX). The stock is up 87.5% year-to-date.The consensus estimate for Gain Therapeutics, Inc.'s current year EPS has increased 5.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).Looking more specifically, Enhabit belongs to the Medical Services industry, a group that includes 62 individual stocks and currently sits at #152 in the Zacks Industry Rank. On average, this group has gained an average of 5.8% so far this year, meaning that EHAB is performing better in terms of year-to-date returns. Gain Therapeutics, Inc., however, belongs to the Medical - Drugs industry. Currently, this 146-stock industry is ranked #75. The industry has moved +5.1% so far this year.Going forward, investors interested in Medical stocks should continue to pay close attention to Enhabit and Gain Therapeutics, Inc. as they could maintain their solid performance.Zacks Naming Top 10 Stocks for 2026Want to be tipped off early to our 10 top picks for the entirety of 2026? History suggests their performance could be sensational.From 2012 (when our Director of Research Sheraz Mian assumed responsibility for the portfolio) through November, 2025, the Zacks Top 10 Stocks gained +2,530.8%, more than QUADRUPLING the S&P 500’s +570.3%.Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2026. Don’t miss your chance to get in on these stocks when they’re released on January 5. Be First to New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Enhabit, Inc. (EHAB): Free Stock Analysis Report Gain Therapeutics, Inc. (GANX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks